An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.

The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.

The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Proposed are a novel flavone derivative and a composition for improving pulmonary fibrosis using the same. The flavone derivative inhibits the TGF-?1 signaling pathway without showing specific cytotoxicity to A549 cells, derived from lung cancer, Hulec-5a cells, derived from pulmonary vessels, and human lung fibroblasts (HLF), thereby inhibiting epithelial-mesenchymal transition (EMT). Additionally, the flavone derivative also shows the effect of regulating the expression of pulmonary fibrosis-related factors in the A549 cells and Hulec-5a cells treated with epidermal growth factor (EGF) or bleomycin, which causes pulmonary fibrosis.

Proposed are a novel flavone derivative and a composition for improving pulmonary fibrosis using the same. The flavone derivative inhibits the TGF-?1 signaling pathway without showing specific cytotoxicity to A549 cells, derived from lung cancer, Hulec-5a cells, derived from pulmonary vessels, and human lung fibroblasts (HLF), thereby inhibiting epithelial-mesenchymal transition (EMT). Additionally, the flavone derivative also shows the effect of regulating the expression of pulmonary fibrosis-related factors in the A549 cells and Hulec-5a cells treated with epidermal growth factor (EGF) or bleomycin, which causes pulmonary fibrosis.